Skip to main content

Advertisement

SpringerLink
Log in

Ultra Rapidly Dissolving Repaglinide Nanosized Crystals Prepared via Bottom-Up and Top-Down Approach: Influence of Food on Pharmacokinetics Behavior

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

The present work was undertaken with the objectives of improving the dissolution velocity, related oral bioavailability, and minimizing the fasted/fed state variability of repaglinide, a poorly water-soluble anti-diabetic active by exploring the principles of nanotechnology. Nanocrystal formulations were prepared by both top-down and bottom-up approaches. These approaches were compared in light of their ability to provide the formulation stability in terms of particle size. Soluplus® was used as a stabilizer and Kolliphor™ E-TPGS was used as an oral absorption enhancer. In vitro dissolution profiles were investigated in distilled water, fasted and fed state simulated gastric fluid, and compared with the pure repaglinide. In vivo pharmacokinetics was performed in both the fasted and fed state using Wistar rats. Oral hypoglycemic activity was also assessed in streptozotocin-induced diabetic rats. Nanocrystals TD-A and TD-B showed 19.86 and 25.67-fold increase in saturation solubility, respectively, when compared with pure repaglinide. Almost 10 (TD-A) and 15 (TD-B)-fold enhancement in the oral bioavailability of nanocrystals was observed regardless of the fasted/fed state compared to pure repaglinide. Nanocrystal formulations also demonstrated significant (p < 0.001) hypoglycemic activity with faster onset (less than 30 min) and prolonged duration (up to 8 h) compared to pure repaglinide (after 60 min; up to 4 h, respectively).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. International Diabetes Federation. 2011: 5th ed.; www.idf.org/diabetesatlas/papers. Accessed 28 April 2014

  2. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet. 2002;41:471–83. doi:10.2165/00003088-200241070-00002.

    Article  CAS  PubMed  Google Scholar 

  3. Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes. Int J Obes Relat Metab Disord. 2000;24 Suppl 3:S21–31. doi:10.1038/sj.ijo.0801422.

    Article  CAS  PubMed  Google Scholar 

  4. Mandic Z, Gabelica V. Ionization, lipophilicity and solubility properties of repaglinide. J Pharm Biomed Anal. 2006;41:866–71. doi:10.1016/j.jpba.2006.01.056.

    Article  CAS  PubMed  Google Scholar 

  5. Hatorp V, Oliver S, Su CA. Bioavailability of repaglinide, a novel anti-diabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. Int J Clin Pharmacol Ther. 1998;36:636–41.

    CAS  PubMed  Google Scholar 

  6. Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol. 2008;56:305–14. doi:10.1046/j.0306-5251.2003.01862.x.

    Article  Google Scholar 

  7. Chang C, Bahadduri PM, Polli JE, Swaan PW, Ekins S. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos. 2006;34:1976–84. doi:10.1124/dmd.106.012351.

    Article  CAS  PubMed  Google Scholar 

  8. Hatorp V, Bayer T. Repaglinide bioavailability in the fed or fasting state [abstract]. J Clin Pharmacol. 1997;37:875.

    Google Scholar 

  9. Yuan G, Jiao L, Xuan Q, Jianjun Z. Co-amorphous repaglinide—saccharin with enhanced dissolution. Int J Pharm. 2013;450:290–5. doi:10.1016/j.ijpharm.2013.04.032.

    Article  Google Scholar 

  10. Kavitha R, Sathali AAH. Enhancement of solubility of repaglinide by solid dispersion technique. Int J Chem Sci. 2012;10:377–90.

    CAS  Google Scholar 

  11. Nicolescu C, Arama C, Nedelcu A, Monciu CM. Phase solubility studies of the inclusion complexes of repaglinide with β-cyclodextrin and β-cyclodextrin derivatives. Farmacia. 2010;58:620–8.

    CAS  Google Scholar 

  12. 12)Troy P, Michal E, Mattucci M, Todd C, Keith P, Williams RO. Rapidly dissolving repaglinide powders produced by the ultra-rapid freezing process. AAPS PharmSciTech 2007; 8: Article 58. doi: 10.1208/pt0803058

  13. Junghanns AH, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3:295–309. doi:10.2147/IJN.S595.

    PubMed Central  CAS  PubMed  Google Scholar 

  14. Peltonen L, Hirvonen J. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. J Pharm Pharmacol. 2010;62:1569–79. doi:10.1111/j.2042-7158.2010.01022.x.

    Article  CAS  PubMed  Google Scholar 

  15. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs 1: absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995;125:91–7. doi:10.1016/0378-5173(95)00122-Y.

    Article  CAS  Google Scholar 

  16. Hardung H, Djuric D, Ali S. Combining HME and solubilisation-soluplus—the solid solution. Drug Deliv Technol. 2010;10:20–7.

    CAS  Google Scholar 

  17. Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by of d-α-tocopheryl PEG 1000 succinate (TPGS). Pharm Res. 1999;16:1550–6. doi:10.1023/A:1015000503629.

    Article  CAS  PubMed  Google Scholar 

  18. Yu L, Bridgers A, Polli J, Vickers A, Long S, Roy A. Vitamin E TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res. 1999;16:1812–7. doi:10.1023/A:1018939006780.

    Article  CAS  PubMed  Google Scholar 

  19. Wu SHW, Hopkins WK. Characteristics of d-α-tocopheryl PEG 1000 succinate for applications as an absorption enhancer in drug delivery systems. Pharm Technol. 1999;23:52–68.

    CAS  Google Scholar 

  20. Verma VSM, Panchagnula R. Enhanced paclitaxel oral absorption with Vitamin E-TPGS: effect on solubility and permeability in vitro, in situ, in vivo. Eur J Pharm Sci. 2005;25:445–53. doi:10.1016/j.ejps.2005.04.003.

    Article  Google Scholar 

  21. Christiansen A, Backensfeld T, Denner K, Weitschies W. Effects of non-ionic surfactants on cytochrome P450-mediated metabolism in vitro. Eur J Pharm Biopharm. 2011;78:166–72. doi:10.1016/j.ejpb.2010.12.033.

    Article  CAS  PubMed  Google Scholar 

  22. Johnson BM, Charman WN, Porter CJH. An in vitro examination of the impact of polyethylene glycol 400, pluronic P85 and vitamin E D-α-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSciTech. 2002;4:E40. doi:10.1208/ps040440.

    Google Scholar 

  23. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage. Pharm Res. 1998;15:11–22. doi:10.1023/A:1011984216775.

    Article  CAS  PubMed  Google Scholar 

  24. Jantratid E, Janssen N, Chokshi H, Tang K, Dressman J. Designing bio-relevant dissolution tests for lipid formulations: case example—lipid suspension of RZ-50. Eur J Pharm Biopharm. 2008;69:776–85. doi:10.1016/j.ejpb.2007.12.010.

    Article  CAS  PubMed  Google Scholar 

  25. Verma S, Gokhale R, Burgess DJ. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm. 2009;380:216–22. doi:10.1016/j.ijpharm.2009.07.005.

    Article  CAS  PubMed  Google Scholar 

  26. He W, Lu Y, Qi JP, Chen LY, Hu FQ, Wu W. Food proteins as novel nanosuspension stabilizers for poorly water-soluble drugs. Int J Pharm. 2013;441:269–78. doi:10.1016/j.ijpharm.2012.11.033.

    Article  CAS  PubMed  Google Scholar 

  27. ICH Harmonised Tripartite Guideline. Stability testing of new drug substances and products Q1A (R2), version 4 dated 6 February, 2003

  28. Cerdeira AM, Mazzotti M, Bruno G. Miconazole nanosuspensions: influence of formulation variables on particle size reduction and physical stability. Int J Pharm. 2010;396:210–8. doi:10.1016/j.ijpharm.2010.06.020.

    Article  CAS  PubMed  Google Scholar 

  29. Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 2006;111:56–64. doi:10.1016/j.jconrel.2005.11.013.

    Article  CAS  PubMed  Google Scholar 

  30. Rahigude A, Bhutada P, Kaulaskar S, Aswar M, Otari K. Participation of antioxidant and cholinergic system in protective effect of naringenin against type-2 diabetes-induced memory dysfunction in rats. Neuroscience. 2012;226:62–72. doi:10.1016/j.neuroscience.2012.09.026.

    Article  CAS  PubMed  Google Scholar 

  31. Ruzilawati AB, Wahab MSA, Imran A, Ismail Z, Gana SH. Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. J Pharm Biomed Anal. 2007;43:1831–5. doi:10.1016/j.jpba.2006.12.010.

    Article  CAS  PubMed  Google Scholar 

  32. Amrani FE, Rhallab A, Alaoui T, Badaoui KE, Chakir S. Hypoglycaemic effect of Thymelaea hirsuta in normal and streptozotocin-induced diabetic rat. J Med Plants Res. 2009;3:625–9.

    Google Scholar 

  33. Andrade-Cetto A, Wiedenfeld H, Revilla MC, Islas S. Hypoglycaemic effect of Equisetum myriochaetum aerial parts on streptozotocin diabetic rats. J Ethnopharmacol. 2000;72:129–33. doi:10.1016/S0378-8741(00)00218-X.

    Article  CAS  PubMed  Google Scholar 

  34. Kipp JE, Wong T, Chung J, Doty MJ, Werling J, Rebbeck CL. Method for preparing submicron particle suspension. U S Patent. 2005;6:884,436.

    Google Scholar 

  35. Guo Z, Zhang M, Li H, Wang J, Kougoulos E. Effect of ultrasound on antisolvent crystallisation process. J Cryst Growth. 2005;273:555–63. doi:10.1016/j.jcrysgro.2004.09.049.

    Article  CAS  Google Scholar 

  36. Dhumal RS, Biradar SV, Paradkar AR, York P. Particle engineering using sonocrystallization: salbutamol sulphate for pulmonary delivery. Int J Pharm. 2009;368:129–37. doi:10.1016/j.ijpharm.2008.10.006.

    Article  CAS  PubMed  Google Scholar 

  37. Yao JH, Elder KR, Guo H, Grant M. Theory and simulation of Ostwald ripening. Physical review B. 1993;47(21):110–25. doi:10.1103/PhysRevB.47.14110.

    Article  Google Scholar 

  38. Teeranachaideekul V, Junyaprasert V, Souto E, Muller R. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. Int J Pharm. 2008;354:227–34. doi:10.1016/j.ijpharm.2007.11.062.

    Article  CAS  PubMed  Google Scholar 

  39. Kesisoglou F, Panmai S, Wu Y. Nanosizing—oral formulation development and biopharmaceutical evaluation. Adv Drug Del Rev. 2007;59:631–44. doi:10.1016/j.addr.2007.05.003.

    Article  CAS  Google Scholar 

  40. Gao L, Liu G, Ma J, Wang X, Zhou L, Li X. Drug nanocrystals: in vivo performances. J Control Release. 2012;160:418–30. doi:10.1016/j.jconrel.2012.03.013.

    Article  CAS  PubMed  Google Scholar 

  41. Li Xi G, Xu Y, Wang Y. Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behaviour in rats. Drug Dev Ind Pharm. 2009;35:827–33. doi:10.1080/03639040802623941.

    Article  Google Scholar 

  42. Parsa A, Saadati R, Abbasian Z, Aramaki SA, Dadashzadeh S. Enhanced permeability of etoposide across everted sacs of rat small intestine by vitamin E-TPGS. Iranian J Pharm Res. 2013;12:37–46.

    CAS  Google Scholar 

  43. Rege BD, Kao JPY, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci. 2002;16:237–46. doi:10.1016/S0928-0987(02)00055-6.

    Article  CAS  PubMed  Google Scholar 

  44. Ivora MD, Paya M, Villar A. A review of natural products and plants as potential anti-diabetic drugs. J Ethnopharmacol. 1989;27:243–75. doi:10.1016/0378-8741(89)90001-9.

    Article  Google Scholar 

  45. Sharma SR, Dwivedi SK, Swarup D. Hypoglycaemic, anti hyperglycaemic and hypolipidemic activities of Cesalpinia bounducella seeds in rats. J Ethnopharmacol. 1997;58:39–44. doi:10.1016/S0378-8741(97)00079-2.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank USV Limited (Mumbai, India) for providing a gift sample of repaglinide. The authors also thank BASF Corporation (Germany) for providing gift samples of the excipients. Rahul Gadadare would also like to thank AICTE (New Delhi, India) for providing financial support in the form of Junior Research Fellowship.

Declaration of Interest

The authors report no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune, Maharashtra, 411038, India

    Rahul Gadadare, Leenata Mandpe & Varsha Pokharkar

Authors
  1. Rahul Gadadare
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leenata Mandpe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Varsha Pokharkar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Varsha Pokharkar.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gadadare, R., Mandpe, L. & Pokharkar, V. Ultra Rapidly Dissolving Repaglinide Nanosized Crystals Prepared via Bottom-Up and Top-Down Approach: Influence of Food on Pharmacokinetics Behavior. AAPS PharmSciTech 16, 787–799 (2015). https://doi.org/10.1208/s12249-014-0267-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-014-0267-8

KEY WORDS

Search

Navigation